2023 Fiscal Year Final Research Report
Development of novel therapies for endocrine cell originated colorectal cancer
| Project/Area Number |
20K17687
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 大腸癌 / 最適化治療 |
|---|
| Outline of Final Research Achievements |
CDX2Low colorectal cancer (CRC) is a subtype of colorectal cancer with a poor prognosis with frequent postoperative recurrence. By establishing live single-cell RNA-Seq. analysis of CDX2Low CRC, the applicant has shown that this colorectal cancer has a unique cell lineage, including an APC gene-independent oncogenic mechanism and endocrine cells. Omics analysis of animal models and clinical specimens also revealed a possible involvement of chronic inflammation in the carcinogenesis of CDX2LowCRC. Disease classification and treatment selection based on cellular origin has been established in hematological malignancies, and the results of this study may lead to the establishment of optimized treatment based on cell lineage for the first time in solid tumor.
|
| Free Research Field |
消化器外科
|
| Academic Significance and Societal Importance of the Research Achievements |
本邦における大腸癌による死亡数はこの20年間で2.5倍と増加の一途にあり、現在では年間5万人を超えている。死因の大半は転移や再発によるものであり、これらの制御機構の解明は、大腸癌の予後改善のための重要課題である。
本研究では根治切除後の転移再発が多い大腸癌のサブタイプであるCDX2低発現大腸癌の細胞起源に着目した解析をおこなった。血液腫瘍では細胞由来による疾患分類や治療選択が標準化されており、本研究の成果も大腸癌の予後改善に貢献できる可能性を持つ。
|
